Lbp Am Sa Reduces Stake in Regeneron Pharmaceuticals

Institutional investor sells 12,873 shares of the biopharmaceutical company's stock

Apr. 18, 2026 at 7:59am

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up image of polished metal gears, cogs, and mechanical components, representing the complex financial infrastructure and institutional investment activity surrounding the biopharmaceutical company Regeneron Pharmaceuticals.An institutional investor's reduced stake in the biopharmaceutical company Regeneron Pharmaceuticals reflects broader shifts in the complex financial landscape surrounding the firm's innovative drug development.Tarrytown Today

Lbp Am Sa, an institutional investor, decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 68.3% in the fourth quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The investor now owns 5,983 shares of the biopharmaceutical company's stock, valued at $4.62 million as of the most recent SEC filing.

Why it matters

Regeneron Pharmaceuticals is a prominent biopharmaceutical company known for its innovative drug discovery technologies and pipeline of therapies. Institutional investor activity in the stock can provide insights into market sentiment and potential future performance.

The details

According to the 13F filing, Lbp Am Sa sold 12,873 shares of Regeneron Pharmaceuticals during the fourth quarter, reducing its total stake in the company by 68.3%. The institutional investor now holds 5,983 shares of the biopharmaceutical company's stock, which were valued at $4.62 million as of the most recent SEC filing.

  • Lbp Am Sa decreased its stake in Regeneron Pharmaceuticals in the fourth quarter of 2025.

The players

Lbp Am Sa

An institutional investor that decreased its stake in Regeneron Pharmaceuticals by 68.3% in the fourth quarter.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Lbp Am Sa's stake in Regeneron Pharmaceuticals could signal a shift in market sentiment or portfolio rebalancing, but does not necessarily indicate any broader trends or concerns about the company's performance or prospects.